Education
About Us
Working with TipRanks
Follow Us
Silence Therapeutics (SLN)
NASDAQ:SLN
SLN Stock Chart & Stats
$5.50
-$0.25(-3.72%)
At close: 4:00 PM EST
$5.50
-$0.25(-3.72%)
Day’s Range― - ―
52-Week Range$1.97 - $7.78
Previous CloseN/A
Volume50.54K
Average Volume (3M)101.05K
Market Cap
$259.79M
Enterprise Value$282.83M
Total Cash (Recent Filing)$85.11M
Total Debt (Recent Filing)-$160.00K
Price to Earnings (P/E)―
Beta1.00
Next Earnings
May 20, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding47,233,948
10 Day Avg. Volume169,902
30 Day Avg. Volume101,050
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-4.61
Price to Sales (P/S)513.72
P/FCF Ratio-4.61
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue505.96
Enterprise Value/Gross Profit822.18
Enterprise Value/Ebitda-3.15
Forecast
1Y Price Target
$27.38Price Target Upside397.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.76
Revenue Forecast (FY)$8.46M
Bulls Say, Bears Say
Bulls Say
Pipeline AdvancementExpedited Phase 2 enrollment and an earlier topline for divesiran shorten development timelines and reduce program risk. As a first-in-class siRNA candidate, sustained progress can materially improve commercialization prospects and strategic leverage with partners over the next few quarters.
Low Financial LeverageVery low debt preserves financial flexibility and limits interest burdens, allowing the company to focus cash on R&D. Low leverage reduces immediate solvency pressure and makes non-debt financing (partnering or equity) more viable as it pursues clinical milestones.
Partner-ready Late-stage AssetHaving a Phase 3–ready, partnerable asset like zerlasiran creates a durable pathway to non-dilutive funding and commercialization expertise. A successful partnership or licensing deal could provide upfront payments and milestones, materially extending runway and de-risking operations.
Bears Say
Heavy Cash BurnPersistent negative operating and free cash flow of roughly -$62M in 2025 indicates the company must repeatedly access external capital. Ongoing burn limits runway, increases dilution risk, and can force delays or reprioritization of clinical programs absent sizable partner or financing events.
Revenue CollapseA near-total drop in revenue eliminates internal funding sources and highlights reliance on intermittent collaboration payments. This structural revenue volatility undermines the company’s ability to self-fund development and raises dependency on partnerships or equity raises for sustainable operations.
Negative Stockholders' EquityNegative equity reflects accumulated losses that have eroded the capital base, weakening balance sheet credibility with investors and counterparties. This structural impairment constrains financing options, may affect covenants or partner terms, and increases refinancing risk until recapitalized.
Silence Therapeutics News
SLN FAQ
What was Silence Therapeutics’s price range in the past 12 months?
Silence Therapeutics lowest stock price was $1.97 and its highest was $7.78 in the past 12 months.
What is Silence Therapeutics’s market cap?
Silence Therapeutics’s market cap is $259.79M.
When is Silence Therapeutics’s upcoming earnings report date?
Silence Therapeutics’s upcoming earnings report date is May 20, 2026 which is in 74 days.
How were Silence Therapeutics’s earnings last quarter?
Silence Therapeutics released its earnings results on Mar 05, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.186 by $0.096.
Is Silence Therapeutics overvalued?
According to Wall Street analysts Silence Therapeutics’s price is currently Undervalued.
Does Silence Therapeutics pay dividends?
Silence Therapeutics does not currently pay dividends.
What is Silence Therapeutics’s EPS estimate?
Silence Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Silence Therapeutics have?
Silence Therapeutics has 47,233,948 shares outstanding.
What happened to Silence Therapeutics’s price movement after its last earnings report?
Silence Therapeutics reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.186. Following the earnings report the stock price went down -4.844%.
Which hedge fund is a major shareholder of Silence Therapeutics?
Currently, no hedge funds are holding shares in SLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Silence Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.38 (397.82% Upside)
$27.38 (397.82% Upside)
Hedge Fund Trend
Decreased
By 70.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-64.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-30.71%
Trailing 12-Months
Company Description
Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
SLN Stock 12 Month Forecast
Average Price Target
$27.38
▲(397.82% Upside)
Technical Analysis
Ownership Overview
22.15%
Insiders
0.10% Mutual Funds
12.23% Other Institutional Investors
65.05% Public Companies and
Individual Investors